Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5351-5354

  Dow, Robert L ^a   Hadcock, John R ^a   Scott, Dennis O ^a   Schneider, Steven R ^a   Paight, Ernest S ^a   Iredale, Philip A ^a   Carpino, Philip A ^a   Griffith, David A ^a   Hammond, Marlys ^a   DaSilva Jardine, Paul ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cannabinoid 1 receptor antagonist; Food intake inhibition; Imidazole isostere; SR 141716

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; HYDRAZIDE; IMIDAZOLE DERIVATIVE; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FOOD INTAKE; NONHUMAN; PHARMACOPHORE; RAT; REACTION ANALYSIS;

ANIMALS; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68949135354     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.130     Document Type: Article

References (30)

1. Kershaw E.E., and Flier J.S. J. Clin. Endocrinol. Metab. 89 (2004) 2548
2. Kirkham T.C. Behav. Pharmacol. 16 (2005) 297
3. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. Endocrinol. Rev. 27 (2006) 73
4. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., and Di Marzo V. J. Clin. Endocrinol. Metab. 91 (2006) 3171
5. Hao S., Avraham Y., Mechoulam R., and Berry E.M. Eur. J. Pharmacol. 392 (2000) 147
6. Engeli S., Böhnke J., Feldpausch M., Gorzelniak K., Janke J., Bátkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A.M., and Jordan J. Diabetes 54 (2005) 2838
7. Kirkham T.C., Williams C.M., Fezza F., and Di Marzo V. Br. J. Pharmacol. 136 (2002) 550
8. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Péleraux A., Pénarier G., Soubrié P., Le Fur G., Galiègue S., and Casellas P. J. FASEB 19 (2005) 1567
9. Thornton-Jones Z.D., Kennett G.A., Benwell K.R., Revell D.F., Misra A., Sellwood D.M., Vickers S.P., and Clifton P.G. Pharmacol. Biochem. Behav. 84 (2006) 353
10. Vickers S.P., Webster L.J., Wyatt A., Dourish C.T., and Kennett G.A. Psychopharmacology (Berl.) 167 (2003) 103
11. Hildebrandt A.L., Kelly-Sullivan D.M., and Black S.C. Eur. J. Pharmacol. 462 (2003) 125
12. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., et al. FEBS Lett. 350 (1994) 240
13. Lin L.S., Lanza Jr. T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Fong T.M., Shen C.P., Lao J., Xiao J.C., Shearman L.P., Stribling D.S., Rosko K., Strack A., Marsh D.J., Feng Y., Kumar S., Samuel K., Yin W., Van der Ploeg L.H., Goulet M.T., and Hagmann W.K. J. Med. Chem. 49 (2006) 7584
14. Griffith D.A., Hadcock J.R., Black S.C., Iredale P.A., Carpino P.A., DaSilva-Jardine P., Day R., DiBrino J., Dow R.L., Landis M.S., O'Connor R.E., and Scott D.O. J. Med. Chem. 52 2 (2009) 234
15. Timbrell J.A. Drug Metab. Rev. 10 (1979) 125
16. Zolla L., and Timperio A.M. Biochem. Cell Biol. 83 (2005) 166
17. Patani G.A., and LaVoie E. J. Chem. Rev. 96 (1996) 3147
18. Shim J.-Y., Welsh W.J., Cartier E., Edwards J.L., and Howlett A.C. J. Med. Chem. 45 (2002) 1447
19. Lange J.H.M., and Kruse C.G. Drug Discovery Today 10 (2005) 693
20. Hurst D., Umejiego U., Lynch D., Seltzman H., Hyatt S., Roche M., McAllister S., Fleischer D., Kapur A., Abood M., Shi S., Jones J., Lewis D., and Reggio P. J. Med. Chem. 49 (2006) 5969
21. Dow, R. L. U.S. Patent Application 2004/077650A1, 2004; Chem. Abstr. 2003, 140, 331785.
22. Barth, F.; Congy, C.; Gueule, P.; Rinaldi-Carmona, M.; Van Broeck, D. PCT Patent Application WO2006/087480A1, 2006.
23. Lee S.H., Seo H.J., Lee S.-H., Jung M.E., Park J.-H., Park H.-J., Yoo J., Yun H., Na J., Kang S.Y., Song K.-S., Kim M., Chang C.-H., Kim J., and Lee J. J. Med. Chem. 51 (2008) 7216
24. Kang S.Y., Lee S.-H., Seo H.J., Jung M.E., Ahn K., Kim J., and Lee J. Bioorg. Med. Chem. Lett. 18 (2008) 2385
25. Sisko J., Kassick A.J., Mellinger M., Filan J.J., Allen A., and Olsen M.A. J. Org. Chem. 65 (2000) 1516
26. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Nature 346 (1990) 561
27. A recent report confirms that blocking (N-methylation) of the hydrazide nitrogen of 1 results in a moderate reduction (4.5-fold) in potency:. Chen J.Z., Han X.-W., Liu Q., Makriyannis A., Wang J., and Xie X.-Q. J. Med. Chem. 49 (2006) 625
28. In vivo protocols are reported in the Supplementary data of Ref. 14.
29. 1 receptor.
30. In: Salaun J. (Ed). Topics in Current Chemistry Vol. 207 (2000), Springer, Berlin, Heidelberg 1-67